Weight Loss Study: GLP-1 Medication and Behavioral Programs
Treatments studied
Part of Hormones & metabolism clinical trials.
This study looks at how GLP-1 medications (like Ozempic or Wegovy) combined with behavioral coaching through Noom affect weight loss and metabolic health over 12 months. You may qualify if you're interested in weight loss and willing to commit to a program for a year.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Speak English and live independently in the community
- Able to walk on your own (with or without aids like a cane)
- Willing to stay in your chosen program for 12 months
- Not pregnant, planning pregnancy, or breastfeeding
- No active eating disorders, cancer, or Type 1 diabetes
- Not taking GLP-1 medication in the past 6 months (if enrolling in GLP-1 arm)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a 6-month behavioral program (including exercise, diet, and mindfulness) designed to help you keep weight off after stopping GLP-1 or similar weight-loss medications. It's for people who have already lost at least 15% of their body weight and stopped or are stopping these medications.
This study looks at how starting a GLP-1 medication (like Wegovy or Ozempic) changes your food choices and eating habits. It may help you understand if these medicines work for weight loss.
This study tests if two different diet programs can help people maintain weight loss for 12 months after stopping a GLP-1 medication (like Ozempic or Wegovy).
This trial tests whether using the Voy app can help people who are already taking a GLP-1 or GIP/GLP-1 weight loss medication lose more weight and improve their health. If you're eligible, the app will be added to your current treatment plan to see if it makes a difference.
This trial tests whether semaglutide can lower heart disease risks in children with extreme obesity. It aims to improve weight and heart health over time.
This study follows people who recently stopped taking a GLP-1 medication (like Wegovy or Ozempic) to understand how weight, eating habits, and daily routines change over time. It aims to help patients and doctors know what to expect after stopping the drug.
Hear when a new Obesity & Overweight trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.